Related Experiment Video
Updated: Mar 31, 2026
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
[What is the place of bioresorbable vascular scaffolds in setting of ST-segment elevation myocardial infarction?]
B Lattuca1, L Schmutz2, B Ledermann2
1Département de cardiologie, CHU Arnaud-de-Villeneuve, 37, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex, France.
Insights
Bioresorbable vascular scaffolds offer potential advantages over drug-eluting stents for myocardial infarction treatment by reducing inflammation and restoring arterial function. Further research is needed to confirm their efficacy in this critical setting.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Inferior ST-segment elevation myocardial infarction (STEMI) requires prompt intervention.
- Drug-eluting stents (DES) are effective but have limitations like chronic inflammation and impaired vasoreactivity.
- Bioresorbable vascular scaffolds (BVS) offer a potential alternative with complete resorption.
Observation:
- A 50-year-old woman presented with STEMI and right coronary artery stenosis.
- Optimal antithrombotic therapy was initiated.
- The discussion focused on stent type selection post-intervention.
Findings:
- Latest-generation DES demonstrate long-term efficacy and safety but pose risks of chronic inflammation and loss of vasoactive function.
- BVS may mitigate these limitations due to their transient nature and resorption within months.
- Limited studies currently exist on BVS use in acute myocardial infarction.
Implications:
- BVS implantation in myocardial infarction patients warrants further investigation.
- Exploring BVS could lead to improved long-term outcomes and reduced complications post-MI.
- This review highlights preliminary findings and future research directions for BVS in acute coronary syndromes.
Abstract:
A 50-year-old woman was admitted for an inferior ST-segment elevation myocardial infarction; immediate coronary angiogram revealed a subocclusive stenosis of the right coronary artery. After optimal antithrombotic treatment, the type of stent could be discussed. The latest generation of drug-eluting stents showed excellent efficacy and safety in the long-term but has limitations such as potential chronic inflammation of the arterial wall and no recovery of vasoactive function. Bioresorbable vascular scaffolds, with complete resorption within several months, may reduce these limitations. Implantation of bioresorbable scaffold in the context of myocardial infarction may be interesting. However, very few studies are currently available in this setting. Preliminary results and perspectives are presented in this review.
